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Abstract 
Background: To determine the clinical characteristics of Continuous Neuropathic Orofacial Pain in patients that su-
ffer Persistent Idiopathic Facial Pain (PIFP), Painful Post-Traumatic Trigeminal Neuropathy (PPTTN) or Burning 
Mouth Syndrome (BMS) and to describe their treatment.
Material and Methods: A retrospective observational study was made, reviewing the clinical history of the patients 
diagnosed with Continuous Neuropathic Orofacial Pain between 2004 and 2011 at the Orofacial Pain Unit of the 
Master of Oral Surgery and Implantology of the University of Barcelona and at the Orofacial Pain Unit of the Te-
knon Medical Center of Barcelona. 
Results: The average age of the patients with Continuous Neuropathic Orofacial Pain was 54.5, with a clear female 
predominance (86.9%, n=20). Of all patients, 60.9% (n=14) were suffering a PIFP, 21.7% (n=5) had a BMS and 
17.4% (n=4) were presenting a PPTTN. The pain quality described by the patients with Continuous Neuropathic 
Orofacial Pain was oppressive (43.47%, n=10), widely represented by patients with PIFP, and burning (39.13%, 
n=9) being the only quality that described patients with BMS. The treatment carried out with the patients was only 
pharmacologic. The most used drugs for the treatment of PIFP and PPTTN were clonazepam (50%, n=9) and ami-
triptyline (44.44%, n=8). However, a 55.5% (n=10) of the patients with PIFP or PPTTN required the association of 
two or more drugs for a correct pain control. All the patients with BMS responded satisfactorily to clonazepam. 
Conclusions: Continuous Neuropathic Orofacial Pain is a little known condition among the general population, 
physicians and dentists. This favors a late diagnosis and inaccurate treatments which entail unnecessary suffering. 
It is important to inform both the general population and health professionals concerning this painful condition.
Key words: Continuous neuropathic orofacial pain, persistent idiopathic facial pain, painful post-traumatic 
trigeminal neuropathy, burning mouth syndrome, atypical odontalgia.
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Introduction
Neuropathic pain is one of the most frustrating conditions 
that challenge dental clinicians because a wrong diagnosis 
may involve the realization of incorrect treatments. Ac-
cording to the International Association for the Study of 
Pain, neuropathic pain is initiated or caused by a primary 
lesion or a nervous system dysfunction (1). Therefore, 
neuropathic pain represents a structural or functional ano-
maly in the peripheral or central nervous system while so-
matic pain is a damage alert system, predominantly (2).
There are two main types of orofacial neuropathic pain: 
episodic neuropathic pain (mostly represented by pa-
roxysmal neuralgias) and continuous neuropathic pain. 
Continuous neuropathic pain differs from episodic neu-
ropathic pain by presenting periods of high and low in-
tensity without complete remission. The diagnostic key 
is the absence of a somatic source of pain (2,3). This 
descriptive retrospective study focuses on patients that 
suffer Persistent Idiopathic Facial Pain (PIFP), Painful 
Post-traumatic Trigeminal Neuropathy (PPTTN) or Bur-
ning Mouth Syndrome (BMS), all included in the group 
of Continuous Neuropathic Orofacial Pain.
The International Classification of Headache Disorders 
of the International Headache Society (IHS) includes 
PIFP, PPTTN and BMS in the group Painful cranial neu-
ropathies and other facial pains (group 13) (4). Okeson 
et al. (2,3,5) divided Continuous Neuropathic Orofacial 
Pain in three types: centrally mediated pain, peripherally 
mediated pain and metabolite polyneuropathies. These 
authors, unlike IHS, classify PPTTN (formerly known 
as Anesthesia Dolorosa) as a peripherally mediated pain 
because they attribute it to nervous deafferentation and 
traumatic neuroma (2,3). 
Persistent Idiopathic Facial Pain, previously called Atypi-
cal Facial Pain, is diagnosed by excluding all other patho-
logies that may cause facial pain in the affected area. PIFP 
is described as a persistent facial and/or oral pain, with 
varying presentations but recurring daily for more than 2 
hours per day over more than 3 months, in the absence of 
clinical neurological deficit (4). It is a chronic form of fa-
cial pain that is normally continuous, deep and poorly lo-
cated, of low to moderate intensity with sporadic episodes 
of intense pain (5,6). A dental cause has been excluded by 
appropriate investigations. If this pain is located in a teeth 
or near a teeth is named Atypical Odontalgia (2,4,7).
Painful post-traumatic trigeminal neuropathy is a dea-
fferentation pain that results from a loss of normal affe-
rent information that reaches the central nervous system 
(CNS). PPTTN is a traumatic neuralgia, generally due to 
a traumatic neuroma formation after a surgical procedure 
or trauma (2). The diagnostic criterion is unilateral facial 
or oral pain following trauma to the trigeminal nerve, 
with clinically evident positive (hyperalgesia, allody-
nia) and/or negative (hypoaesthesia, hypoalgesia) signs 
of trigeminal nerve dysfunction. Pain is located in the 
distribution of the same trigeminal nerve and it has to be 
developed within 3-6 months of the traumatic event (4).
Finally, Burning Mouth Syndrome is an intraoral bur-
ning or dysaesthetic sensation on the tongue, lips, gin-
giva and/or oral mucosa, recurring daily for more than 2 
hours per day over more than 3 months, without clinica-
lly evident causative lesions. Oral mucosa is of normal 
appearance and clinical examination including sensory 
testing is normal (2,4,8,9).
The objective of this study is to determine the clinical 
characteristics of Continuous Neuropathic Orofacial 
Pain in patients that suffer PIFP, PPTTN or BMS and to 
describe their treatment.
Material and Methods 
A retrospective observational study was made by means 
of reviewing the clinical records of patients diagnosed 
with Continuous Neuropathic Orofacial Pain seen bet-
ween 2004 and 2011 at the Orofacial Pain Unit of the 
Master of Oral Surgery and Implantology of University of 
Barcelona and the Orofacial Pain Unit of Teknon Medical 
Center of Barcelona. The study design was approved by 
the Research and Ethics Committees of University. 
The patients included were under clinical diagnosis of 
PIFP, PPTTN and BMS, according to group 13 of the 
International Classification of Headache Disorders of 
the International Headache Society. The patients with 
incomplete protocols were excluded.
The variables collected were divided in three categories:
- Patient variables: gender, age at the moment of diagno-
sis and the presence of systemic disease or psychologi-
cal/psychiatric disorders. 
- Pain variables: clinical diagnosis, quality, intensity, 
anatomical location, duration, pain aggravators and re-
lievers, the possible trigger, time of evolution to clinical 
diagnosis and the concomitant symptoms of pain.
- Therapeutic variables: prescribed drug treatment and 
its side effects.
The patient data and the pain characteristics that were 
used for the statistical study were registered during the 
first visit to the Orofacial Pain Units. All the patients 
were subjected to the same protocolized clinical history. 
The quality of pain was registered by showing the pa-
tients a list of descriptive adjectives: oppressive, elec-
trical, burning, shooting, sharp and throbbing. In order 
to register the pain intensity, the patients were asked to 
classify it as low, moderate or intense. 
Tables 1, 2 and 3 show the pain characteristics of each 
patient according to the clinical diagnosis: PIFP, PPTTN 
or BMS.
Microsoft Access for Windows was used for data co-
llection. A descriptive analysis was performed with the 
Statistical Package for the Social Sciences for Windows 
(SPSS v15.0; SPSS Inc. Chicago, IL, USA, University 
of Barcelona license).
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1 2 3 4 5
Age (years old) 62 43 68 56 70
Gender Male Female Female Female Female
Quality Burning Burning Burning Burning Burning
Intensity Moderate
Intense
Low Moderate Moderate Low
Moderate
Affected area Tongue Tongue Tongue
Palate
Tongue
Gingiva
Tongue
Lips
Oral Mucosa
Duration Continuous Continuous Fluctuating
(during the day)
Continuous Fluctuating
(during the day)
Trigger Unknown Unknown Unknown Unknown Unknown
Table 1. Characteristics of pain in patients with Burning Mouth Syndrome. 
Age
(years old)
Gender Quality Intensity Area affected Duration Trigger
1 58 Female Opressive Low Superior molars Continuous Dental implant 
surgery
2 37 Female Opressive Moderate Superior molars Continuous Unknown
3 53 Female Opressive
Throbbing
Moderate
Intense
Superior premo-
lars and molars
Continuous Placement of fixed 
prostheses
4 57 Female Electrical
Sharp
Moderate Intermenton area Fluctuating 
(during the day)
Dental implant 
surgery
5 54 Female Burning
Electrical
Moderate Premaxilla Continuous Lip hair waxing
6 34 Male Electrical Low
Moderate
Infraorbital aera Fluctuating 
(during the day)
Unknown
7 50 Female Opressive
Burning
Moderate Infraorbital area Continuous Depression
8 50 Female Opressive
Burning
Moderate Superior molars Fluctuating 
(during the day)
Extraction of 2.8
9 47 Male Electrical Low
Moderate 
Intense
Superior molars Fluctuating 
(during the day)
Extraction of 1.6
10 53 Female Opressive Moderate Infraorbital area Continuous Unknown
11 67 Female Opressive
Sharp
Intense Superior molars Continuous Extraction of 1.8
12 58 Female Opressive Moderate Superior molars Fluctuating 
(during the day)
Extraction of 2.8
13 52 Female Opressive Moderate
Intense
Premaxilla Fluctuating 
(during the day)
Dental implant 
surgery
14 51 Female Throbbing Moderate Infraorbital area Fluctuating
(during the day)
Unknown
Table 2. Characteristics of pain in patients with Persistent Idiophatic Facial Pain.
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Table 3. Characteristics of pain in patients with Anesthesia Dolorosa.
1 2 3 4
Age
(years old)
55 67 60 48
Gender Female Female Female Female
Quality Sharp
Electrical
Electrical
Sharp
Burning Opressive
Shooting
Intensity Moderate Moderate Low
Moderate
Moderate
Intensive
Area affected Intermenton
zone
Inferior
lip
Infraorbital
area
Lip and inferior 
premolars
Duration Continuous Continuous Continuous Continuous
Trigger Dental implant 
surgery
Tumoral exeresis Extraction of 
premolars
Extraction of 3.8
Sensory 
alterations
Hyperesthesia 
on gingiva
Hyperesthesia of 
the inferior lip
Parestesia on 
infraorbital 
area
Parestesia of the 
inferior lip
Results
The study sample consisted of 23 patients with Conti-
nuous Neuropathic Orofacial Pain, with a clear female 
predominance (86.9%, n=20). The average age of pa-
tients was 54.5 (range 34-70). Of all patients, 60.9% 
(n=14) were suffering a PIFP, 21.7% (n=5) had a BMS 
and 17.4% (n=4) were presenting a PPTTN. The mean 
evolution time, namely the period between onsets of 
the symptoms and diagnosis, was 28.1 months (ranging 
from 0.5 to 96). 
PIFP were located at the maxilla in 64.3% (n=9) of ca-
ses, at the infraorbital area in 28.6% (n=4) and one case 
(7.1%, n=1) at the intermenton (chin) zone. The location 
of PPTTN was 50% (n=2) on the inferior lip, and 25% 
(n=1) on the intermenton zone and the infraorbital zone. 
All the BMS were located in the tongue (100%, n=5), 
although three patients also referred having burning pain 
in the palate, oral mucosa and lips. 
The pain quality described by the patients with Conti-
nuous Neuropathic Orofacial Pain was (n=23): oppressi-
ve (43.47%, n=10), widely represented by patients with 
PIFP, burning (39.13%, n=9), being the only quality that 
described patients with BMS, electrical (26.08%, n=6), 
sharp (17.39%, n=4), throbbing (8.69%, n=2) and 1 pa-
tient with PPTTN referred shooting pain (4.34%, n=1). 
The 39.13% (n=9) of cases reported two or more types 
of pain quality. 
The most prevalent pain intensity was moderate (86.9%, 
n=20), followed by low (26.08%, n=6) and severe in-
tensity (26.08%, n=6). Variations of pain intensity were 
described by 34.78% (n=8) of participants.
Stress increased the pain intensity for 34.8% (n=8) of 
cases and 43.5% (n= 10) of the patients presented other 
systemic diseases and psychiatric/psychological disor-
ders related or not to the chronic pain.
All the patients with PPTTN (n=4) reported that their 
pain was triggered by a surgical procedure on the affec-
ted nervous zone and all the patients presented sensory 
alterations on the affected area (hyperesthesia, dysesthe-
sia or paresthesia). The 71.43% (n=10) of patients that 
suffered a PIFP reported a pain trigger, for instance a 
surgical procedure, depression or lip hair waxing. No 
patients with PIFP presented sensibility alterations on 
the painful area. The patients with BMS did not report 
any pain triggering.
The treatment carried out with the patients was only 
pharmacologic. We divided the patients into two thera-
peutic groups. The first group describes the treatments 
performed for patients with PIFP and PPTTN. Patients 
with BMS comprised the second group.
PIFP and PPTTN (n=18) patients may often respond 
similarly to the same drug treatment, interindividual 
differences being essential. Association of two or more 
drugs for the correct pain control was required for 55.5% 
(n=10) of these patients. The 50% (n=9) of cases were 
treated with clonazepam, 44.44% (n=8) received ami-
triptyline and 33.33% (n=6) duloxetine. Besides, venla-
faxine (n=1, 5.55%), nortriptyline (n=1, 5.55%), prega-
balin (n=1, 5.55%) and gabapentine (n=1, 5.55%) were 
used. The drug most associated with the other ones was 
clonazepam. The drug of choice that we first used in all 
the patients of this group was amitriptyline. The most 
described side effects were drowsiness (n=2), fatigue 
(n=3), xerostomia (n=4), cardiovascular (n=2) and sen-
sory alterations (n=2), among others.
All the patients with BMS (n=5) responded satisfacto-
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rily to treatment with clonazepam, at doses of 1-1.5 mg/
day. The described side effects were somnolence (n=2), 
fatigue (n=1) and aggressiveness (n=1).
Discussion
To date, the prevalence of PIFP in the general population 
is still unknown. According to this study, a higher preva-
lence of PIFP has been found among women. The hig-
hest prevalence of cases reported by literature is around 
the fourth decade of life, unlike in our sample that 
appears in the fifties (3,7,10). Although all ages may be 
affected by this painful condition, a case of impairment 
in childhood has not yet been described in literature. In 
our study, the youngest patient was 34 years old (7). Aty-
pical Odontalgia presents as tooth pain or pain in a site 
where a tooth was extracted, in the absence of clinical 
and radiographic evidence of tooth pathology (11-13). 
PIFP has been described to occur in 3% to 6% of patients 
who undergo endodontic treatment (11,14). However, 
any patients in our study referred a previous endodontic 
treatment as a pain trigger. The referred causes were an 
oral surgery procedure (tooth extraction, periapical sur-
gery and dental implant surgery) and other non-dental 
related causes such as history of depression, sinusitis 
and lip hair waxing. Although PIFP has been very little 
related to dental implant placement in the whole litera-
ture, we present four cases (15).
According to this work, some studies report that molars 
and premolars are the most frequently involved teeth 
and that the maxilla is more often affected than the man-
dible (7,16,17).
Regarding to PPTTN, it has not been described to have 
a gender tendency. All the patients have sensory alte-
rations (hyperesthesia, dysesthesia or paresthesia) and 
relate that the start of pain was a surgical procedure 
like dental implant surgery (3,4,18). Renton and Yilmaz 
(12) reported a sample of 90 patients having iatrogenic 
lesions of inferior alveolar nerve: 60% appeared after 
third molar extraction, 19% after inferior alveolar block 
anaesthesia, 18% after dental implant placement and 8% 
were associated with endodontic treatment. These pa-
tients described allodynia, paresthesia, dysesthesia and 
hyperesthesia (2-4). 
According to the available literature, tricyclic antidepres-
sants (TCAs) seem to be the most effective medication 
for the treatment of neuropathic chronic orofacial pain 
(7,19-21). TCAs such as amitriptyline inhibit the recap-
ture of serotonin and norepinephrine, neurotransmitters 
which are known to be present in CNS sites involved in 
pain inhibition (22). Therefore, it is suggested that TCAs 
could mediate therapeutic effects by increasing the ac-
tivity of CNS pain inhibitory mechanism. Additionally, 
amitriptyline has affinity for muscarinic, histaminic and 
β-adrenergic receptors (14). Maybe this lower affinity is 
the responsible of its therapeutic effect. The amitriptyli-
ne, unlike other TCAs used in the treatment of chronic 
neuropathic pain (such as nortriptyline and desiprami-
ne), presents a high affinity for the above mentioned 
receptors (23). Other studies show that β-blockers and 
some anticonvulsants as clonazepam, gabapentine and 
baclofen seem to be fairly effective in the treatment of 
continuous neuropathic orofacial pain (15,19,24). Topi-
cal medications such as capsaicin, at a concentration of 
0.025%, also give good results in certain patients with 
this disorder (2,15).
In agreement with these findings, the most used drugs in 
our patients diagnosed with PPTTN and PFIP were clo-
nazepam and amitriptyline. The drug of choice that we 
first used in all these patients was amitriptyline. Howe-
ver, in a third of patients with PPTTN and PIFP, we had 
to prescribe two or more drugs to achieve an adequate 
pain control.
BMS is a painful intraoral sensation characterized by the 
burning sensation of the tongue, lips, gingiva and/or oral 
mucosa (2). All the patients of our study were females 
(n=5) and described a burning pain on the tongue; besi-
des, some of them referred pain on the lips, gingiva and 
palate. The literature shows that the age of presentation 
of BMS varies from 50 to 70 years old, being rare before 
the third decade (2,25). Typically, it initiates around or 
after the menopausal period. Our group had an average 
age of 59.8 years old; the youngest patient was 43 years 
old. The intensity of pain ranges from low to intense, 
appearing while waking up or later during the day. BMS 
does not cause incapacity and it usually has a sudden on-
set (2,8). The appearance of the oral soft tissue is normal 
or reveals few clinical abnormalities (2). From our pa-
tients, only one had an oral lichen planus on the painful 
area. The diagnostic criteria that we used are described 
in figure 1.
Clonazepam is the most commonly reported drug in li-
terature to treat BMS (2, 26, 27). This anticonvulsant 
benzodiazepine is often used with an initial dose of 0.25 
mg/day and after, the dose increases to 0.25 mg/week 
to achieve adequate pain control, with a maximum of 3 
mg/day (2, 26). Heckmann et al. (27) performed a ran-
domized placebo-controlled clinical trial on clonazepam 
for the treatment of BMS and proved its therapeutic effi-
cacy. Other drugs, such as TCAs (excluding amitriptyli-
ne because it induces hyposialia), gabapentine, paroxe-
tine and chlordiazepoxide have been proposed for the 
treatment of BMS but with lower efficacy than clonaze-
pam (27-29). In our study, pain was correctly controlled 
in all patients with BMS by means of clonazepam.
A recent study by Yang and Huang (30) proposes the 
use of a soft laser for the control of pain in BMS. They 
recommend the application of 1 to 7 sessions of laser. 
They describe a decreasing in pain of 47.6%. A similar 
result was reached in another study on the use of soft 
lasers in the treatment of pain in BMS (31).
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Fig. 1. Proposal of criteria to consider in establishing the diagnosis of Burning Mouth Syndrome.
Conclusions
Continuous neuropathic orofacial pain is a little known 
condition among the general population, physicians and 
dentists. Unfortunately, this favors a late diagnosis and 
an inaccurate treatment which entails unnecessary suffe-
ring for the patient. It is important to inform the general 
population and health professionals concerning this pa-
inful condition. 
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